Publicaciones en las que colabora con María Consuelo Montejo Rubio (12)

2023

  1. Micropartículas de Celecoxib-PLGA para el tratamiento de procesos inflamatorios pulmonares

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  2. XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

    Sociedad Española de Farmacia Industrial y Galénica

2022

  1. Celecoxib Microparticles for Inhalation in COVID-19-Related Acute Respiratory Distress Syndrome

    Pharmaceutics, Vol. 14, Núm. 7

  2. Functionalization of Morin-Loaded PLGA Nanoparticles with Phenylalanine Dipeptide Targeting the Brain

    Pharmaceutics, Vol. 14, Núm. 11

2021

  1. Sulfasalazine microparticles targeting macrophages for the treatment of inflammatory diseases affecting the synovial cavity

    Pharmaceutics, Vol. 13, Núm. 7

  2. Vectorización de agentes antiinflamatorios a macrófagos para potenciar su actividad utilizando micropartículas

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 262-264

2020

  1. Potential Active Targeting of Gatifloxacin to Macrophages by Means of Surface-Modified PLGA Microparticles Destined to Treat Tuberculosis

    AAPS PharmSciTech, Vol. 21, Núm. 1

2017

  1. Surface-modified gatifloxacin nanoparticles with potential for treating central nervous system tuberculosis

    International Journal of Nanomedicine, Vol. 12, pp. 1959-1968

2013

  1. Development and validation of a reversed-phase liquid chromatography method for the quantification of meloxicam in liposomes

    Acta Chromatographica, Vol. 25, Núm. 4, pp. 639-653

2010

  1. Effective antiproliferative effect of meloxicam on prostate cancer cells: Development of a new controlled release system

    International Journal of Pharmaceutics, Vol. 387, Núm. 1-2, pp. 223-229

2008

  1. PLGA/PEG-derivative polymeric matrix for drug delivery system applications: Characterization and cell viability studies

    International Journal of Pharmaceutics, Vol. 352, Núm. 1-2, pp. 50-57

1996

  1. Biopharmaceutic study of commercial nitrofurantoin oral dosage forms

    S.T.P. Pharma Sciences, Vol. 6, Núm. 6, pp. 445-449